Synaffix has expanded the utility of it clinical-stage GlycoConnect™ platform to also deliver immune cell engagers. Key highlights of corresponding AACR poster:
- GlycoConnect™ technology enables site-specific attachment of both cytotoxic payloads and small protein fragments to antibodies without genetic engineering
- Small protein fragments (like scFvs) can be attached to generate bispecific T cell engagers with tailored stoichiometry, where the 2:1 format may be of particular interest to minimize cytokine release syndrome (CRS)
- Trimming the antibody glycan fully abrogates binding to Fc-γ receptors, thus nihilating effector function
